Galmed Pharma (GLMD) Misses Q4 EPS by 1c

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.29), $0.01 worse than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• Galmed completes Colospan acquisition under restructured terms